Maxim analysts are weighing in on the small-cap biopharmaceutical company Galena Biopharma Inc (NASDAQ:GALE), and Canadian biotech company AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the companies presented clinical data at the European Cancer Congress in Vienna, Austria.

Galena Biopharma Inc

Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Galena Biopharma, with a $7 price target, after the company presented data from the GALE-301, Galena’s peptide-based cancer immunotherapy to prevent the recurrence of endometrial and ovarian cancer, at the European Cancer Congress 2015 in Vienna, Austria.

McCarthy noted, “Galena’s vaccines are at comparable stages in development to those from other companies that were rewarded with lucrative partnerships, driving valuation inflections, in our view. Additionally, we believe the cancer vaccine space remains undervalued relative to CAR-T and thus an attractive valuation exists for investors.”

Furthermore, “GALE-301 is the second peptide-based immunotherapy making significant progress in oncology. The company’s lead peptide immunotherapy, NeuVax (prevention of breast cancer recurrence) , is in an over-enrolled pivotal phase III trial (“PRESENT”) with interim data expected in YE-2015.”

“As Galena’s breast cancer vaccine NeuVax is in a fully enrolled pivotal phase III trial, it’s important to highlight the value proposition for cancer vaccine’s overall, a space we believe is undervalued,” the analyst added.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason McCarthy has a total average return of -10.5% and a 19.2% success rate. McCarthy is ranked #3494 out of 3759 analysts.

Out of the 8 analysts polled by TipRanks, 5 rate Galena Biopharma stock a Buy, 2 rate the stock a Hold and 1 recommends Sell. With a return potential of 224%, the stock’s consensus target price stands at $5.17.

AEterna Zentaris Inc. (USA)

Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a $2 price target, after the company announced that its lead oncology compound, zoptarelin doxorubicin met the primary end-point of an investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer.

Kolbert noted, “We see compelling value ahead in this company across multiple programs. Success with the pivotal program is not being factored into the current valuation by Wall Street, in our opinion, nor is the return of Macrilen. In fact we see Macrilen as representing a paradigm shift in the adult growth hormone deficiency (AGHD) marketplace. The current test, insulin tolerance is long and burdensome compared to Macrilen. As such Macrilen could expand the market.”

According to,analyst Jason Kolbert has a total average return of -13.4% and a 27.8% success rate. Kolbert has a -74.3% average return when recommending AEZS, and is ranked #3754 out of 3759 analysts.

Out of the 3 analysts polled by TipRanks, 2 rate Aeterna Zentaris stock a Buy, while 1 rates the stock a Hold. With a return potential of 1022.1%, the stock’s consensus target price stands at $1.13.